Market Overview

UPDATE: JMP Securities Initiates Coverage On Pernix Therapeutics On Positive Growth Outlook


In a report published Tuesday, JMP Securities analyst Oren G. Livnat initiated coverage on Pernix Therapeutics Holdings Inc (NASDAQ: PTX) with a Market Outperform rating and $13.00 price target.

In the report, JMP Securities noted, “We are initiating coverage of Pernix Therapeutics with a Market Outperform rating and $13 price target. Pernix is a commercial-stage, specialty pharmaceuticals company in the early innings of an aggressive acquisition strategy following a recent management overhaul. The company has quickly transformed, via acquisitions, from an unprofitable branded generics company to a CNS-focused, highly profitable, growth company with a productive sales force with an appetite and capacity for additional growth. We believe PTX can significantly grow its key assets and execute on additional business development. Clearly, investors anticipate additional deals, in our view, and the stock reflects credit for value beyond the limited patent life of key drivers. However, we believe: 1) there is substantial fundamental upside to 2016-2018 Street estimates; 2) the company could make potentially transformative M&A moves sooner rather than later; and 3) life-cycle strategies could extend current franchise values. Our $13 target is based on 8.4x 2016 P/E and 6.6x EV/EBITDA multiples that are >40% below Spec Pharma averages.”

Pernix Therapeutics closed on Monday at $9.39.

Latest Ratings for PTX

Aug 2016Brean CapitalDowngradesBuyHold
Mar 2016OppenheimerDowngradesOutperformPerform
Mar 2016Brean CapitalMaintainsBuy

View More Analyst Ratings for PTX
View the Latest Analyst Ratings

Posted-In: JMP Securities Oren G. LivnatAnalyst Color Initiation Analyst Ratings


Related Articles (PTX)

View Comments and Join the Discussion!

Latest Ratings

PEPMorgan StanleyReiterates137.0
AZRXH.C. WainwrightMaintains7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More

Live Cattle Futures Open Higher